These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
6. Ribozymes: use as anti-HIV therapeutic molecules. Dropulic B; Elkins DA; Rossi JJ; Sarver N Antisense Res Dev; 1993; 3(1):87-94. PubMed ID: 8495108 [No Abstract] [Full Text] [Related]
7. Catalytic antisense RNA (ribozymes): their potential and use as anti-HIV-1 therapeutic agents. Rossi JJ; Sarver N Adv Exp Med Biol; 1992; 312():95-109. PubMed ID: 1514448 [No Abstract] [Full Text] [Related]
8. Gene therapy for HIV. Lever AM Sex Transm Infect; 2001 Apr; 77(2):93-6. PubMed ID: 11287684 [No Abstract] [Full Text] [Related]
9. Therapeutic potential and mechanism of action of oligonucleotides and ribozymes. Lavrovsky Y; Chen S; Roy AK Biochem Mol Med; 1997 Oct; 62(1):11-22. PubMed ID: 9367793 [TBL] [Abstract][Full Text] [Related]
10. Utility of antioncogene ribozymes and antisense oligonucleotides in reversing drug resistance. Funato T Methods Mol Med; 2005; 106():215-33. PubMed ID: 15375319 [No Abstract] [Full Text] [Related]
11. Clinical trial results of GEM91 show activity against advance HIV. AIDS Patient Care STDS; 1997 Aug; 11(4):290-1. PubMed ID: 11361850 [No Abstract] [Full Text] [Related]
13. The application of ribozymes to HIV infection. Rossi JJ Curr Opin Mol Ther; 1999 Jun; 1(3):316-22. PubMed ID: 11713796 [TBL] [Abstract][Full Text] [Related]
14. The potential use of catalytic RNAs in therapy of HIV infection and other diseases. Rossi JJ; Cantin EM; Sarver N; Chang PF Pharmacol Ther; 1991; 50(2):245-54. PubMed ID: 1763136 [TBL] [Abstract][Full Text] [Related]
15. Sense antisense nonantisense. Can these novel antivirals knock HIV senseless? Chang HE; Mascolini M J Int Assoc Physicians AIDS Care; 1995 Feb; 1(1):11-8. PubMed ID: 11362229 [TBL] [Abstract][Full Text] [Related]
16. Gene therapeutic agents: the use of ribozymes, antisense, and RNA decoys for HIV-1 infection. Smythe JA; Symonds G Inflamm Res; 1995 Jan; 44(1):11-5. PubMed ID: 7664023 [No Abstract] [Full Text] [Related]
17. Delivery of antiviral agents in liposomes. Düzgüneş N; Simões S; Slepushkin V; Pretzer E; Flasher D; Salem II; Steffan G; Konopka K; Pedroso de Lima MC Methods Enzymol; 2005; 391():351-73. PubMed ID: 15721391 [TBL] [Abstract][Full Text] [Related]
18. Design and evaluation of clinically relevant SOFA-HDV ribozymes targeting HIV RNA. Scarborough RJ; Lévesque MV; Perreault JP; Gatignol A Methods Mol Biol; 2014; 1103():31-43. PubMed ID: 24318884 [TBL] [Abstract][Full Text] [Related]
19. Antisense activity of an anti-HIV oligonucleotide conjugated to linear and branched high molecular weight polyethylene glycols. Bonora GM; Tocco G; Zaramella S; Veronese FM; Pliasunova O; Pokrovsky A; Ivanova E; Zarytova V Farmaco; 1998; 53(10-11):634-7. PubMed ID: 10205850 [TBL] [Abstract][Full Text] [Related]
20. Antisense technologies have a future fighting neurodegenerative diseases. Seidman S; Eckstein F; Grifman M; Soreq H Antisense Nucleic Acid Drug Dev; 1999 Aug; 9(4):333-40. PubMed ID: 10463077 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]